UY33110A - Moduladores de CRTH2 - Google Patents
Moduladores de CRTH2Info
- Publication number
- UY33110A UY33110A UY33110A UY33110A UY33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A
- Authority
- UY
- Uruguay
- Prior art keywords
- crth2 modulators
- crth2
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28984109P | 2009-12-23 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33110A true UY33110A (es) | 2011-07-29 |
Family
ID=43735997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY33110A UY33110A (es) | 2009-12-23 | 2010-12-16 | Moduladores de CRTH2 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8674115B2 (es) |
| EP (1) | EP2516416A1 (es) |
| JP (1) | JP5731538B2 (es) |
| KR (1) | KR20120098908A (es) |
| CN (1) | CN102822163B (es) |
| AR (1) | AR079492A1 (es) |
| AU (1) | AU2010333829A1 (es) |
| BR (1) | BR112012017756A2 (es) |
| CA (1) | CA2785191A1 (es) |
| CL (1) | CL2012001712A1 (es) |
| CO (1) | CO6640201A2 (es) |
| CR (1) | CR20120343A (es) |
| EA (1) | EA201200855A1 (es) |
| EC (1) | ECSP12011996A (es) |
| MX (1) | MX2012007239A (es) |
| PH (1) | PH12012501280A1 (es) |
| SG (1) | SG181900A1 (es) |
| TW (1) | TW201130810A (es) |
| UY (1) | UY33110A (es) |
| WO (1) | WO2011079007A1 (es) |
| ZA (1) | ZA201204527B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140187795A1 (en) * | 2010-12-08 | 2014-07-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators and preparation thereof |
| WO2012130633A1 (en) * | 2011-03-25 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as crth2 antagonists |
| WO2013155422A1 (en) | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
| JPWO2017104728A1 (ja) * | 2015-12-16 | 2018-11-29 | 幸久 村田 | 食物アレルギー治療薬 |
| PT3445767T (pt) | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
| CN115397813A (zh) * | 2020-04-16 | 2022-11-25 | 豪夫迈·罗氏有限公司 | 联苯衍生物 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CN1071924A (zh) * | 1991-10-29 | 1993-05-12 | 纳幕尔杜邦公司 | 除草的三唑羧酸酰胺 |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| EP0837052B1 (en) | 1995-06-21 | 2006-08-23 | Shionogi & Co., Ltd. | Bicyclic amino derivatives and pgd 2 antagonist containing the same |
| US5859042A (en) * | 1995-09-27 | 1999-01-12 | Ono Pharmaceutical Co., Ltd. | Five membered heterocyclic compounds |
| EP0945450B1 (en) | 1996-12-12 | 2005-05-11 | Shionogi & Co., Ltd. | Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same |
| CZ297324B6 (cs) | 1996-12-13 | 2006-11-15 | Shionogi & Co., Ltd. | Benzothiofenkarboxamidové deriváty a antagonisty PGD2, které je obsahují |
| WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE60115411D1 (de) | 2000-04-12 | 2006-01-05 | Merck Frosst Canada & Co Kirkl | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| CA2440803A1 (en) | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| EP1424325A4 (en) | 2001-09-07 | 2005-12-21 | Ono Pharmaceutical Co | INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT |
| KR20040044856A (ko) | 2001-09-07 | 2004-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체 화합물 |
| CA2463272C (en) | 2001-10-22 | 2009-11-17 | Laura Cook Blumberg | Piperazine derivatives with ccr1 receptor antagonist activity |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1492789B1 (en) | 2002-04-08 | 2006-06-07 | Pfizer Limited | Tropane derivatives as ccr5 modulators |
| EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
| AU2003231513A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Pgd2 receptor antagonist |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| OA12894A (en) | 2002-08-12 | 2006-10-13 | Pfizer Prod Inc | Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide. |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| US7482355B2 (en) | 2002-08-24 | 2009-01-27 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AU2003277285B2 (en) | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20040092529A1 (en) | 2002-10-30 | 2004-05-13 | Pfizer Inc | Methods of using piperazine derivatives |
| US20040097554A1 (en) | 2002-10-30 | 2004-05-20 | Pfizer Inc | Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents |
| US20040116441A1 (en) | 2002-10-30 | 2004-06-17 | Pfizer Inc | Methods of using sulfonic acid derivatives |
| SE0203828D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Chemical compounds |
| ZA200505523B (en) * | 2002-12-20 | 2006-09-27 | Amgen Inc | Asthma and allergic inflammation modulators |
| SE0203820D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
| AR042628A1 (es) | 2002-12-20 | 2005-06-29 | Astrazeneca Ab | Derivados de piperidina como moduladores del receptor ccr5 |
| EP1653926A1 (en) | 2003-08-04 | 2006-05-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| BRPI0511676A (pt) * | 2004-05-29 | 2008-01-08 | 7Tm Pharma As | uso medicinal de ligandos receptores |
| US20080119456A1 (en) | 2004-05-29 | 2008-05-22 | Trond Ulven | Substituted Thiazoleacetic Acid as Crth2 Ligands |
| UA85512C2 (ru) | 2004-05-29 | 2009-01-26 | 7Тм Фарма А/С | Лиганды рецептора crth2 для применения в медицине |
| US20090105218A1 (en) * | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| US7999119B2 (en) * | 2006-07-22 | 2011-08-16 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
| EP2268281A4 (en) * | 2008-02-15 | 2012-05-02 | Abbott Lab | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS |
-
2010
- 2010-12-16 SG SG2012046678A patent/SG181900A1/en unknown
- 2010-12-16 AU AU2010333829A patent/AU2010333829A1/en not_active Abandoned
- 2010-12-16 UY UY33110A patent/UY33110A/es not_active Application Discontinuation
- 2010-12-16 MX MX2012007239A patent/MX2012007239A/es active IP Right Grant
- 2010-12-16 AR ARP100104664A patent/AR079492A1/es not_active Application Discontinuation
- 2010-12-16 CA CA2785191A patent/CA2785191A1/en not_active Abandoned
- 2010-12-16 TW TW099144402A patent/TW201130810A/zh unknown
- 2010-12-16 JP JP2012546053A patent/JP5731538B2/ja not_active Expired - Fee Related
- 2010-12-16 BR BR112012017756A patent/BR112012017756A2/pt not_active Application Discontinuation
- 2010-12-16 EP EP10798887A patent/EP2516416A1/en not_active Withdrawn
- 2010-12-16 WO PCT/US2010/060671 patent/WO2011079007A1/en not_active Ceased
- 2010-12-16 US US12/969,840 patent/US8674115B2/en active Active
- 2010-12-16 KR KR1020127019130A patent/KR20120098908A/ko not_active Withdrawn
- 2010-12-16 CN CN201080059094.XA patent/CN102822163B/zh not_active Expired - Fee Related
- 2010-12-16 EA EA201200855A patent/EA201200855A1/ru unknown
- 2010-12-16 PH PH1/2012/501280A patent/PH12012501280A1/en unknown
-
2012
- 2012-06-19 ZA ZA2012/04527A patent/ZA201204527B/en unknown
- 2012-06-22 EC ECSP12011996 patent/ECSP12011996A/es unknown
- 2012-06-22 CR CR20120343A patent/CR20120343A/es unknown
- 2012-06-22 CL CL2012001712A patent/CL2012001712A1/es unknown
- 2012-06-22 CO CO12105121A patent/CO6640201A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA201200855A1 (ru) | 2013-04-30 |
| BR112012017756A2 (pt) | 2016-04-19 |
| SG181900A1 (en) | 2012-08-30 |
| CL2012001712A1 (es) | 2012-12-07 |
| US8674115B2 (en) | 2014-03-18 |
| CA2785191A1 (en) | 2011-06-30 |
| KR20120098908A (ko) | 2012-09-05 |
| AU2010333829A1 (en) | 2012-07-12 |
| EP2516416A1 (en) | 2012-10-31 |
| US20110150834A1 (en) | 2011-06-23 |
| JP5731538B2 (ja) | 2015-06-10 |
| WO2011079007A1 (en) | 2011-06-30 |
| JP2013515726A (ja) | 2013-05-09 |
| CN102822163B (zh) | 2016-01-20 |
| ZA201204527B (en) | 2013-09-25 |
| CR20120343A (es) | 2013-01-25 |
| AR079492A1 (es) | 2012-02-01 |
| PH12012501280A1 (en) | 2013-02-04 |
| ECSP12011996A (es) | 2012-10-30 |
| CO6640201A2 (es) | 2013-03-22 |
| MX2012007239A (es) | 2012-10-15 |
| CN102822163A (zh) | 2012-12-12 |
| TW201130810A (en) | 2011-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012010640A2 (pt) | novos moduladores de quinase | |
| PT2414891T (pt) | Dispositivos electrocrómicos | |
| BRPI1007450A2 (pt) | dispositivo de exibição | |
| BRPI1013318A2 (pt) | dispositivo de exibição | |
| BRPI1014636A2 (pt) | moduladores de gpr 119 | |
| BRPI0924840A2 (pt) | dispositivo de exibição | |
| DK2512451T3 (da) | Modulator | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112010002728A5 (de) | Turboinhalator | |
| DK2435410T3 (da) | LXR-modulatorer | |
| EP2490796C0 (en) | AGITATION DEVICE | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BR112012000040A2 (pt) | dispositivo de exibição | |
| FR2947857B1 (fr) | Agencement de deshuileur | |
| BR112013011865A2 (pt) | moduladores de gpr119 | |
| BR112012005432A2 (pt) | dispositivo de exibição | |
| EP2477076A4 (en) | FIXING DEVICE | |
| BRPI1010159A2 (pt) | bistuti | |
| UY33110A (es) | Moduladores de CRTH2 | |
| BRPI1011789A2 (pt) | dispositivo de exibição | |
| BR112012003630A2 (pt) | dispositivo de exibição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20181127 |